UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
SHOCKWAVE MEDICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-38829 | 27-0494101 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| 5403 Betsy Ross Drive, Santa Clara, California | 95054 | |||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Hajime Tada
General Counsel
(510) 279-4262
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed:
| x | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting from January 1 to December 31, 2023 | ||||
| o | Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the fiscal year ended _____________. | ||||
| Item 1.01. | Conflict Minerals Disclosure and Report. | ||||
A copy of the Conflict Minerals Report of Shockwave Medical, Inc. (“Shockwave”) for the reporting from January 1 to December 31, 2023 is filed as Exhibit 1.01 to this specialized disclosure report on Form SD and is also available at Shockwave’s website at https://ir.shockwavemedical.com/financial-information/sec-filings.
| Item 1.02. | Exhibit. | ||||
Shockwave has filed, as an exhibit to this Form SD, the Conflict Minerals Report required by Item 1.01 of this Form.
| Item 3.01. | Exhibits. | ||||
| Exhibit Number | Description of Document | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
| SHOCKWAVE MEDICAL, INC. | ||||||||||||||
Dated: May 28, 2024 | By: | /s/ Renee Gaeta | ||||||||||||
| Name: | Renee Gaeta | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
Exhibit 1.01
Shockwave Medical, Inc.
Conflict Minerals Report
For the Reporting Period January 1, 2023 to December 31, 2023
This Conflict Minerals Report (“CMR”) has been prepared by Shockwave Medical, Inc. (herein referred to, alternatively, as “Shockwave,” “we” and “our”). This CMR for the reporting period January 1, 2023 to December 31, 2023 is presented to comply with the final conflict minerals implementing rule (“Final Rule”) promulgated by the Securities and Exchange Commission (“SEC”), as modified by guidance issued by the SEC’s Division of Corporation Finance on April 29, 2014 and the SEC order issued on May 2, 2014. The Final Rule was adopted by the SEC to implement reporting and disclosure requirements related to conflict minerals as directed by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 as codified in Section 13(p) of the Securities Exchange Act of 1934. The Final Rule imposes certain reporting obligations on SEC registrants whose manufactured products contain conflict minerals that are necessary to the functionality or production of their products. “Conflict minerals” are currently defined by the SEC as cassiterite, columbite-tantalite (coltan), gold, wolframite, or their derivatives, which the SEC has currently limited to tin, tantalum and tungsten.
To comply with the Final Rule, we conducted due diligence on the origin, source and chain of custody of the conflict minerals that were necessary to the functionality or production of the products that we manufactured or contracted to manufacture to attempt to ascertain whether these conflict minerals originated in the Democratic Republic of the Congo or an adjoining country (collectively, “Covered Countries”) and financed or benefited armed groups (as defined in Section 1, Item 1.01(d)(2) of Form SD) in any of these countries.
Pursuant to guidance issued by the SEC’s Division of Corporation Finance on April 29, 2014 and the SEC order issued May 2, 2014, Shockwave is not required to describe any of its products as “DRC conflict free” (as defined in Section 1, Item 1.01(d)(4) of Form SD), “DRC conflict undeterminable” (as defined in Section 1, Item 1.01(d)(5) of Form SD) or “having not been found to be ‘DRC conflict free,’” and therefore makes no conclusion in this regard in the report presented herein. Furthermore, given that Shockwave has not voluntarily elected to describe any of its products as “DRC conflict free,” an independent private sector audit of the report presented herein has not been conducted.
COMPANY OVERVIEW
Shockwave is a medical device company focused on developing and commercializing novel technologies that transform the care of patients with cardiovascular disease. We aim to establish a new standard of care for the treatment of calcified cardiovascular disease through our differentiated and proprietary local delivery of sonic pressure waves, which we refer to as intravascular lithotripsy (“IVL”). Our IVL system (our “IVL System”), which leverages our IVL technology (our “IVL Technology”), is a minimally invasive, easy-to-use, and safe way to improve outcomes for patients with calcified cardiovascular disease. Additionally, we aim to transform the standard of care for patients suffering from refractory angina with our coronary sinus reducer (the “Reducer”) technology, an innovative technology that creates a permanent, controlled narrowing of the coronary sinus.
| I. | Product Overview | ||||||||||||||||
IVL
Our IVL System includes a generator, connector cable and a variety of IVL catheters designed to treat Peripheral Artery Disease and Coronary Artery Disease. Our IVL System employs our IVL Technology to crack calcium through short, microsecond bursts of sonic pressure waves, which are generated within the IVL catheter, travel through the vessel, and crack calcium without harming the soft tissue. Our IVL catheters utilize multiple lithotripsy emitters that are integrated into a standard, balloon-catheter platform.
Reducer
Our Reducer is a treatment for patients with refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. A refractory angina patient, by definition, is resistant to other existing interventional cardiology therapies and is not receiving adequate relief from available drug regimens to manage their chest pain, shortness of breath and other debilitating symptoms.
| II. | Supply Chain Overview | ||||||||||||||||
The manufacturing of our IVL catheters is principally done at our facilities in Santa Clara, California, but a third-party contract manufacturer manufactures a portion of our demand for certain catheters. Our electronics (i.e., generators and connector cables) are produced by original equipment manufacturing partners using our design specifications.
For purposes of this CMR, references to our “products” refer to our IVL catheters, generators, connector cables and Reducer, and references to our “suppliers” refer to certain product suppliers.
| III. | Conflict Minerals Analysis and Reasonable Country of Origin Inquiry | ||||||||||||||||
Based upon a review of our products and our reasonable country of origin inquiry (“RCOI”), we have concluded that:
| • | Our products contain conflict minerals that are necessary to the production or functionality of such products; and | ||||||||||||||||||||||||||||||||||
| • | We are unable to determine whether the conflict minerals present in our products originate in the Covered Countries. | ||||||||||||||||||||||||||||||||||
| IV. | Design of Due Diligence Measures | ||||||||||||||||
We designed our due diligence with respect to the source and chain of custody of the conflict minerals contained in our products based on the five-step framework set forth in the Third Edition of the Organisation for Economic Co-operation and Development’s Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas and the supplements thereto (the “OECD Guidance”).
| V. | Due Diligence Measures Performed by Shockwave | ||||||||||||||||
Shockwave performed the following due diligence measures in accordance with the OECD Guidance and the Final Rule:
OECD Guidance Step #1: Establish Strong Company Management Systems
| • | We have established a Responsible Minerals Sourcing Policy (the “Policy”) that sets forth our commitments regarding the sourcing of conflict minerals and our expectations of our suppliers regarding the same. The Policy can be found on our website at https://ir.shockwavemedical.com/esg. | ||||||||||||||||||||||||||||||||||
| • | The implementation of our RCOI and the conducting of due diligence on the source and chain of custody of our necessary conflict minerals are managed by Shockwave’s legal and quality departments. | ||||||||||||||||||||||||||||||||||
| • | The legal and quality staff responsible for conflict minerals compliance (i) have received training regarding conflict minerals compliance and (ii) are required to be familiar with the Policy and with Shockwave’s conflict minerals-related processes. | ||||||||||||||||||||||||||||||||||
| • | Material conflict minerals-related records, including completed CMRTs (as defined below), will be maintained by Shockwave for a period of five (5) years from the date of creation. | ||||||||||||||||||||||||||||||||||
| • | The Policy has been made available to suppliers on our website. | ||||||||||||||||||||||||||||||||||
| • | Interested parties can report violations of the Policy at www.shockwavemedical.ethicspoint.com. | ||||||||||||||||||||||||||||||||||
OECD Guidance Step #2: Identify and Assess Risk in the Supply Chain
| • | We undertook an analysis of our products and an analysis of our suppliers to identify parts and subassemblies that we believe could contain one or more conflict materials. | ||||||||||||||||||||||||||||||||||
| • | Based on our assessment of the likelihood that the products contain conflict minerals, we either (i) requested that suppliers complete in full the Responsible Minerals Initiative’s (the “RMI”) Conflict Minerals Reporting Template (the “CMRT”) or (ii) sent inquiries to suppliers to confirm if conflict minerals were intentionally added or used in the products supplied or in the production process and, if so, requested that such suppliers complete in full the CMRT. The CMRT is designed to request from Shockwave’s suppliers sufficient information regarding such suppliers’ practices with respect to the sourcing of conflict minerals to enable Shockwave to comply with its requirements under the Final Rule. | ||||||||||||||||||||||||||||||||||
| • | Shockwave’s legal and quality departments manage and oversee the collection of information reported on the CMRT by Shockwave’s suppliers. | ||||||||||||||||||||||||||||||||||
OECD Guidance Step #3: Design and Implement a Strategy to Respond to Identified Risks
| • | If, on the basis of areas of concern that are identified as a result of either (i) the supplier data acquisition or engagement processes or (ii) the receipt of information from other sources, we determine that a supplier is sourcing conflict minerals that are directly or indirectly financing or benefiting armed groups, we will enforce the Policy by means of a series of escalations. | ||||||||||||||||||||||||||||||||||
| • | Such escalations may range from prompt engagement with the supplier to resolve the sourcing issue, to requiring such supplier to implement a risk management plan (which plan may involve, as appropriate, remedial action up to and including disengagement from upstream suppliers), to disengagement by Shockwave from the applicable supplier. | ||||||||||||||||||||||||||||||||||
OECD Guidance Step #4: Carry Out Independent Third-Party Audit of Supply Chain Due Diligence at Identified Points in the Supply Chain
Given that we do not have a direct relationship with the smelters and refiners that process the conflict minerals that are present in our products, we rely on the RMI to conduct third-party audits of smelters and refiners.
OECD Guidance Step #5: Report on Supply Chain Due Diligence
As required by the Final Rule, we have filed a Form SD and this Conflict Minerals Report as an exhibit thereto for the 2023 reporting year. The Form SD and Conflict Minerals Report are also available on our website at https://ir.shockwavemedical.com/financial-information/sec-filings.
| VI. | Smelters and Refiners | ||||||||||||||||
Based on our assessment of the likelihood that the products contain conflict minerals, we sent the CMRT and/or letters of inquiry to 94 suppliers. As a result of Shockwave’s RCOI, 17 suppliers provided completed CMRTs to Shockwave and 70 suppliers stated that conflict minerals were not intentionally added or used in the products supplied to Shockwave or in the production process.
The 17 suppliers that completed the CMRT identified approximately 348 smelters and refiners from which they source conflict minerals that appear on the RMI’s Standard Smelter List. Some suppliers may have reported to us
smelters and refiners that were not in our supply chain due to over-inclusiveness in the information received from their suppliers, or for other reasons. Of those smelters and refiners, 246 smelters and refiners, or approximately 70%, have successfully completed an assessment against the applicable RMI Responsible Minerals Assurance Process (“RMAP”) standard or an equivalent cross-recognized assessment.
The information contained in the preceding two paragraphs is based on supplier responses received through May 22, 2024. Smelter and refiner status information is provided as of May 24, 2024.
The smelters and refiners analyzed may not be all of the smelters and refiners in our supply chain, because the suppliers did not identify all of the smelters and refiners in their supply chains, and because we did not receive responses from all suppliers. Due to our position in the supply chain, we rely on our suppliers for accurate smelter and refiner information, and our RCOI and due diligence measures do not provide absolute certainty regarding the origin of conflict minerals contained in our products.
| VII. | Steps to Mitigate Risk | ||||||||||||||||
We intend to take the following steps to mitigate the risk that conflict minerals benefit armed groups:
| • | Continue to engage with suppliers to obtain complete CMRTs; and | ||||||||||||||||||||||||||||||||||
| • | Encourage the development of supplier capabilities to perform conflict minerals-related due diligence. | ||||||||||||||||||||||||||||||||||
FORWARD-LOOKING STATEMENTS
Statements relating to risk mitigation and other statements herein are forward-looking in nature and are based on Shockwave’s management’s current expectations or beliefs. These forward-looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors that may be outside of Shockwave’s control and that could cause actual events to differ materially from those expressed or implied by the statements made herein, and Shockwave reserves the right to change its processes and policies related to conflict minerals.
DOCUMENTS INCORPORATED BY REFERENCE
Unless otherwise expressly stated herein, any documents, third-party materials, or references to websites (including Shockwave’s) are not incorporated by reference in, or considered to be a part of this CMR, unless expressly incorporated by reference herein.